ScripsAmerica, Inc Moves into Major Markets

After commencing operations in 2010, ScripsAmerica, Inc. (OTC BB: SCRC) delivers pharmaceutical products to a wide range of end users across the health care industry, including long-term care sites, hospitals, and Government and home care agencies. ScripsAmerica is already sharing in a U$25 million dollar contract that Marlex Pharmaceuticals is fulfilling for the US Department of Defense (DOD) and Defense Logistics Agency (DLA).

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

America’s Pharmaceutical Company

New Castle, DE (PRWEB) February 19, 2013

After commencing operations in 2010, ScripsAmerica, Inc (OTC BB: SCRC) delivers pharmaceutical products to a wide range of end users across the health care industry, including long-term care sites, hospitals, and Government and home care agencies. Positioned in the center of the pharmaceutical value chain, ScripsAmerica receives purchase orders from large pharmaceutical distributors, contracts with pharmaceutical packagers and their manufacturers to process orders to end user’s specifications, and delivers product to a wide range of customers across the health care industry.

As part of the growth program, ScripsAmerica is in the process of acquiring Marlex Pharmaceuticals. Acquisition of the targeted pharmaceutical packager will expand ScripsAmerica’s customer list approximately two-fold, as well as serving to streamline supplier and vendor relations. Under the current agreement and Letter of Intent ScripsAmerica is already sharing in a U$25 million dollar contract Marlex is fulfilling for the US Department of Defense (DOD) and Defense Logistics Agency (DLA).

ScripsAmerica obtained the exclusive rights to the manufacturer’s patented process for RapiMed. RapiMed is part of the Oral Delivery Technology (ODT) and what is commonly referred to as Quickmelt. Quickmelt refers to an oral drug delivery formulation, which entails drugs in tablet form that can be taken without water and will dissolve in the mouth in less than 30 seconds. Quickmelt’s primary advantages over other oral dosage forms include patient friendliness, consumer convenience, sustained release and high active dose capabilities. Initially Acetaminophen for pain and fever relief for children will be in the RapiMed form then migraine headache relief, sleep aids, and then generic drugs will enter the RapiMeds family.

ScripsAmerica revenues were U$3.2 Million in 2010, U$5.9 Million in 2011, and an estimated U$5.7 Million in 2012. 2013 looks to be the best year for ScripsAmerica with exciting expansions and acquisitions positioning for a major piece of the market place.

For an interview with Robert Schneiderman C.E.O. of ScripsAmerica email or call:
Bob(at)scripsamerica(dot)com
Ph: 215-741-7006
America’s Pharmaceutical Company

Copyright © 2013 All rights reserved.
PR: http://www.MassMedia77.com Sound Marketing is Smart Business

Safe Harbor Statement

This report includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2010 and beyond could differ materially from the Company’s current expectations.

Forward-looking statements are identified by words such as “anticipates,” “projects,” “expects,” “plans,” “intends,” “believes,” “estimates,” “targets,” and other similar expressions that indicate trends and future events.        

Factors that could cause the Company’s results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company’s products and services, the frequency, magnitude and timing of paper and other raw-material-price changes, general business and economic conditions beyond the Company’s control, timing of the completion and integration of acquisitions, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of the MyC3 initiative and other cost-containment strategies, and the Company’s success in attracting and retaining key personnel. Additional information concerning factors that could cause actual results to differ materially from those projected is contained in the Company’s filing with The Securities and Exchange Commission. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information since these statements may no longer be accurate or timely.

Analysts’ Compensation: Mass Media 77, Inc. who in part or in whole may be responsible for the preparation of this report may receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which include revenues from, among other business units, Institutional Equities and Investment Banking and restricted stock.

Information has been obtained from sources believed to be reliable but Mass Media 77, Inc or its affiliates and/or subsidiaries (collectively Mass Media 77, Inc.) do not warrant its completeness or accuracy. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. Periodic updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other publicly available information. Additional information may be available upon request.


Contact

Follow us on: Contact's Facebook Contact's Twitter